As monotherapy or in combination with tamsulosin for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of need for BPH-related surgery. Unlabeled use(s):
Plasma concentrations of dutasteride may be elevated, increasing the risk of adverse reactions. Use with caution. However, the change in dutasteride exposure with coadministration of diltiazem or verapamil is not considered clinically important, and no dosage adjustment is recommended.
When dutasteride is taken with food, the dutasteride Cmax is reduced 10% to 15%. This reduction is not considered to be clinically important. Dutasteride may be taken with or without food.